These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32886425)

  • 1. Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey.
    Orgel E; Freyer DR; Ullrich NJ; Hardy KK; Thomas SM; Dvorak CC; Esbenshade AJ
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28647. PubMed ID: 32886425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
    Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature.
    Meijer AJM; Diepstraten FA; Ansari M; Bouffet E; Bleyer A; Fresneau B; Geller JI; Huitema ADR; Kogner P; Maibach R; O'Neill AF; Papadakis V; Rajput KM; Veal GJ; Sullivan M; van den Heuvel-Eibrink MM; Brock PR
    J Clin Oncol; 2024 Jun; 42(18):2219-2232. PubMed ID: 38648563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Special considerations in the design and implementation of pediatric otoprotection trials.
    Freyer DR; Orgel E; Knight K; Krailo M
    J Cancer Surviv; 2023 Feb; 17(1):4-16. PubMed ID: 36637630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
    Freyer DR; Brock PR; Chang KW; Dupuis LL; Epelman S; Knight K; Mills D; Phillips R; Potter E; Risby D; Simpkin P; Sullivan M; Cabral S; Robinson PD; Sung L
    Lancet Child Adolesc Health; 2020 Feb; 4(2):141-150. PubMed ID: 31866182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
    Viglietta V; Shi F; Hu QY; Ren Y; Keilty J; Wolff H; McCarthy R; Kropp J; Weber P; Soglia J
    Invest New Drugs; 2020 Oct; 38(5):1463-1471. PubMed ID: 32157599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431.
    Orgel E; Knight KR; Villaluna D; Krailo M; Esbenshade AJ; Sung L; Freyer DR
    Pediatr Blood Cancer; 2023 Jul; ():e30550. PubMed ID: 37416942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
    Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
    Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
    Duinkerken CW; de Weger VA; Dreschler WA; van der Molen L; Pluim D; Rosing H; Nuijen B; Hauptmann M; Beijnen JH; Balm AJM; de Boer JP; Burgers JA; Marchetti S; Schellens JHM; Zuur CL
    Otol Neurotol; 2021 Jun; 42(5):678-685. PubMed ID: 33710154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    Brock PR; Maibach R; Childs M; Rajput K; Roebuck D; Sullivan MJ; Laithier V; Ronghe M; Dall'Igna P; Hiyama E; Brichard B; Skeen J; Mateos ME; Capra M; Rangaswami AA; Ansari M; Rechnitzer C; Veal GJ; Covezzoli A; Brugières L; Perilongo G; Czauderna P; Morland B; Neuwelt EA
    N Engl J Med; 2018 Jun; 378(25):2376-2385. PubMed ID: 29924955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
    J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
    Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z
    Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous N-Acetylcysteine to Prevent Cisplatin-Induced Hearing Loss in Children: A Nonrandomized Controlled Phase I Trial.
    Orgel E; Knight KR; Chi YY; Malvar J; Rushing T; Mena V; Eisenberg LS; Rassekh SR; Ross CJD; Scott EN; Neely M; Neuwelt EA; Muldoon LL; Freyer DR
    Clin Cancer Res; 2023 Jul; 29(13):2410-2418. PubMed ID: 37134194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it.
    Brock P; Meijer A; Kogner P; Ansari M; Capra M; Geller J; Heuvel-Eibrink MVD; Knight K; Kruger M; Lindemulder S; Maibach R; O'Neill A; Papadakis V; Rajput K; Bleyer A; Bouffet E; Sullivan M
    Pediatr Blood Cancer; 2023 May; 70(5):e30248. PubMed ID: 36772889
    [No Abstract]   [Full Text] [Related]  

  • 18. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
    Freyer DR; Brock P; Knight K; Reaman G; Cabral S; Robinson PD; Sung L
    Lancet Child Adolesc Health; 2019 Aug; 3(8):578-584. PubMed ID: 31160205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials.
    Minasian LM; Frazier AL; Sung L; O'Mara A; Kelaghan J; Chang KW; Krailo M; Pollock BH; Reaman G; Freyer DR
    Cancer Med; 2018 Jul; 7(7):2951-2959. PubMed ID: 29846043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
    Ishikawa E; Sugimoto H; Hatano M; Nakanishi Y; Tsuji A; Endo K; Kondo S; Wakisaka N; Murono S; Ito M; Yoshizaki T
    Acta Otolaryngol; 2015 Sep; 135(9):919-24. PubMed ID: 25861690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.